NasdaqCM:XAIR

Stock Analysis Report

Executive Summary

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Share Price & News

How has Beyond Air's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.1%

XAIR

-0.003%

US Medical Equipment

1.3%

US Market


1 Year Return

-18.2%

XAIR

11.9%

US Medical Equipment

5.9%

US Market

Return vs Industry: XAIR underperformed the US Medical Equipment industry which returned 11.9% over the past year.

Return vs Market: XAIR underperformed the US Market which returned 5.9% over the past year.


Shareholder returns

XAIRIndustryMarket
7 Day-5.1%-0.003%1.3%
30 Day-14.7%-3.0%-1.9%
90 Day-21.9%-0.6%-1.8%
1 Year-18.2%-18.2%12.8%11.9%8.3%5.9%
3 Yearn/a69.6%64.5%45.6%36.2%
5 Yearn/a129.6%104.0%66.1%47.9%

Price Volatility Vs. Market

How volatile is Beyond Air's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Beyond Air undervalued compared to its fair value and its price relative to the market?

5.67x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: XAIR ($4.21) is trading above our estimate of fair value ($1.43)

Significantly Undervalued: XAIR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: XAIR is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: XAIR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate XAIR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XAIR is overvalued based on its PB Ratio (5.7x) compared to the US Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is Beyond Air forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

77.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XAIR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: XAIR is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: XAIR's loss is forecast to worsen by 0% next year.

Revenue vs Market: XAIR's revenue (66.8% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: XAIR's revenue (66.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if XAIR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Beyond Air performed over the past 5 years?

-22.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: XAIR is unprofitable, and losses have increased over the past 5 years at a rate of -22.1% per year.

Accelerating Growth: Unable to compare XAIR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XAIR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: XAIR has a negative Return on Equity (-140.14%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: XAIR is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: XAIR is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Beyond Air's financial position?


Financial Position Analysis

Short Term Liabilities: XAIR's short term assets ($12.3M) exceeds its short term liabilities ($5.1M)

Long Term Liabilities: XAIR's short term assets (12.3M) exceeds its long term liabilities (179.3K)


Debt to Equity History and Analysis

Debt Level: XAIR's debt to equity ratio (1.9%) is considered satisfactory

Reducing Debt: XAIR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: XAIR has a low level of unsold assets or inventory.

Debt Coverage by Assets: XAIR's debt is covered by short term assets (assets are 83.366250x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable XAIR has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: XAIR is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -17.3% per year.


Next Steps

Dividend

What is Beyond Air's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate XAIR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XAIR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if XAIR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XAIR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XAIR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Beyond Air's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Steve Lisi (48yo)

2.3yrs

Tenure

US$2,839,664

Compensation

Mr. Steven Adam Lisi, also known as Steve, has been the Chief Executive Officer of AIT Therapeutics, Inc. since June 14, 2017. Mr. Lisi serves as Chief Executive Officer and Chairman of the Board at Mico I ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Steve's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.0yrs

Average Tenure

48yo

Average Age

Experienced Management: XAIR's management team is considered experienced (2 years average tenure).


Board Age and Tenure

2.3yrs

Average Tenure

49.5yo

Average Age

Experienced Board: XAIR's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Doug Beck (58yo)

    Chief Financial Officer

    • Tenure: 0.9yrs
    • Compensation: US$550.01k
  • Amir Avniel (45yo)

    Co-Founder

    • Tenure: 2.8yrs
    • Compensation: US$1.35m
  • Asher Tal

    Senior VP of Clinical Research & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Steve Lisi (48yo)

    CEO & Chairman of the Board

    • Tenure: 2.3yrs
    • Compensation: US$2.84m
  • Ali Ardakani

    Senior Vice President of Device & Business Development

    • Tenure: 0yrs
  • Duncan Fatkin

    Chief Commercial Officer

    • Tenure: 0.8yrs
    • Compensation: US$417.10k
  • Giora Davidai

    Chief Medical Officer

    • Tenure: 2yrs
  • Adam Newman

    Chief Legal Officer & General Counsel

    • Tenure: 1.6yrs
    • Compensation: US$971.99k

Board Members

  • Yoori Lee (46yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$83.73k
  • Ron Bentsur (53yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$83.73k
  • Amir Avniel (45yo)

    Co-Founder

    • Tenure: 2.8yrs
    • Compensation: US$1.35m
  • Asher Tal

    Senior VP of Clinical Research & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Yossef Av-Gay (57yo)

    Member of Scientific Advisory Board

    • Tenure: 1.8yrs
    • Compensation: US$75.00k
  • Steve Lisi (48yo)

    CEO & Chairman of the Board

    • Tenure: 2.3yrs
    • Compensation: US$2.84m
  • Andrew Colin

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Erick Lucera (51yo)

    Director

    • Tenure: 2.2yrs
    • Compensation: US$95.38k
  • Hugh O'Brodovich

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • John Clancy

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Beyond Air, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Beyond Air, Inc.
  • Ticker: XAIR
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$45.251m
  • Shares outstanding: 10.74m
  • Website: https://www.ait-pharm.com

Number of Employees


Location

  • Beyond Air, Inc.
  • 825 East Gate Boulevard
  • Suite 320
  • Garden City
  • New York
  • 11530
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XAIRNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2017

Biography

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery system ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 00:36
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.